ERBB2 and cancer: Pre-existing cardiovascular comorbidities (such as hypertension, diabetes, and dyslipidemia), direct cardiotoxic effects of various cancer therapies (e.g., anthracyclines, HER2-targeted agents, fluoropyrimidines, and chest radiation), indirect cardiotoxicity through electrolyte imbalances or autonomic dysfunction, cancer-related inflammation, and a prothrombotic state often induced by the malignancy itself [7–9] are among these factors.